Lexaria Bioscience (LEXX)
NASDAQ:LEXX
LEXX Stock Chart & Stats
$0.62
-$0.08(-3.57%)
At close: 4:00 PM EST
$0.62
-$0.08(-3.57%)
Day’s Range― - ―
52-Week Range$0.46 - $1.55
Previous CloseN/A
Volume56.77K
Average Volume (3M)986.05K
Market Cap
$15.23M
Enterprise Value$7.27M
Total Cash (Recent Filing)$5.27M
Total Debt (Recent Filing)$94.39K
Price to Earnings (P/E)―
Beta0.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,787,445
10 Day Avg. Volume354,178
30 Day Avg. Volume986,050
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)5.30
Price to Sales (P/S)22.44
P/FCF Ratio-1.51
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue19.77
Enterprise Value/Gross Profit19.77
Enterprise Value/Ebitda-0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsLexaria is now searching for a pharmaceutical partner to advance the clinical program for DehydraTECH-liraglutide, which could lead to significant developments in its clinical pathway.
Market AdoptionImprovement in GLP-1 drugs’ safety profile could lower patient dropout rates and enhance market adoption.
Safety And TolerabilityDehydraTECH-semaglutide has demonstrated a favorable safety and tolerability profile.
Bears Say
Analyst RecommendationAnalyst's recommendation adjusts the 12-month price target to $5 from $7.
Commercial SuccessDehydraTECH formulations need to demonstrate a comparable level of efficacy to marketed GLP-1 drugs to be commercially successful.
Efficacy ComparisonInterim efficacy results are not as robust as Rybelsus.
Lexaria Bioscience News
LEXX FAQ
What was Lexaria Bioscience’s price range in the past 12 months?
Lexaria Bioscience lowest stock price was $0.46 and its highest was $1.55 in the past 12 months.
What is Lexaria Bioscience’s market cap?
Lexaria Bioscience’s market cap is $15.23M.
When is Lexaria Bioscience’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lexaria Bioscience’s earnings last quarter?
Currently, no data Available
Is Lexaria Bioscience overvalued?
According to Wall Street analysts Lexaria Bioscience’s price is currently Overvalued.
Does Lexaria Bioscience pay dividends?
Lexaria Bioscience does not currently pay dividends.
What is Lexaria Bioscience’s EPS estimate?
Lexaria Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexaria Bioscience have?
Lexaria Bioscience has 24,787,445 shares outstanding.
What happened to Lexaria Bioscience’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lexaria Bioscience?
Currently, no hedge funds are holding shares in LEXX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexaria Bioscience
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Technical Analysis
Ownership Overview
4.58% Insiders
2.45% Mutual Funds
1.91% Other Institutional Investors
89.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---